Hugo Sigman and his wife, Silvia Gold, lead Grupo Insud, a conglomerate of companies linked to the pharmaceutical, agribusiness and cultural sectors, among others. Among the firms that make up this group is mAbxience, which since 2009 has specialized in the research and development of monoclonal antibodies. With the arrival of the pandemic, the company played a key role, since it reached an agreement with the national and Mexican governments and AstraZeneca to produce the vaccine against Covid-19 in the plant that the laboratory owns in Garin, in Greater Buenos Aires.
Argentina | Grupo Insud | Health
September 18, 2022 | 10:30 PM
Read this story inPortuguese or inSpanish